High-flying biotech Intercept Pharmaceuticals (ICPT -2.25%) enjoyed a 516% gain last week, but shares have tumbled this week. After yesterday's 18% dive, shares dropped another 30% today. In the following video, analyst Max Macaluso discusses what caused today's drop and the key issues that long-term investors need to focus on.
Free Article
Why Biotech Boomer Intercept Pharmaceuticals, Inc. Tumbled Again
By Max Macaluso
–
Jan 14, 2014 at 8:04PM
NASDAQ: ICPT
Intercept Pharmaceuticals
Market Cap
$575M
Today's Change
(-2.25%) -$0.31
Current Price
$13.48
Price as of March 30, 2023, 4:00 p.m. ET
Why did Intercept shares tumble today?
Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson and also owns shares of Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Intercept Pharmaceuticals
ICPT
$13.48
(-2.25%)
$0.31
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why Intercept Pharmaceuticals Stock Is Soaring Today
Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript
Intercept Pharmaceuticals, inc (ICPT) Q2 2021 Earnings Call Transcript
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
Are These the Next Meme Stocks?
402%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.